Burden of digestive system malignancies and its impact on life expectancy in China, 2004–2021

作者：Ting Hu, Shiyue Wang, Yingying Wang, Xinlong Wang, Lin Shang, Kaijuan Wang · 发表于：eGastroenterology · 年份：2025 · DOI：10.1136/egastro-2024-100148 · 被引用次数：7 · 研究领域：Colorectal Cancer Screening and Detection、Healthcare Systems and Reforms、Global Health Care Issues

Digestive system malignant tumours (DSMTs) are prevalent, with oesophageal, gastric, colorectal, liver and pancreatic cancers being the most common types according to the fifth edition of the WHO’s classification of DSMTs. Data from GLOBOCAN 2022 showed that oesophageal, gastric, colorectal, liver and pancreatic cancer accounted for approximately 4.6%, 6.8%, 9.3%, 7.8% and 4.8% of global cancer deaths and ranked seventh, fifth, second, third and sixth, respectively. Prior research has forecasted a substantial increase in new cases and mortality rates of digestive system malignancies by 2040, with a projected global increase of 58% in new cases and a more pronounced surge of 73% in deaths.1 This alarming growth forecast underscores the impending massive public health burden associated with these diseases. In China, the cancer profile exhibits similarities with both developed and developing countries. Specifically, colorectal, gastric and liver cancers represent a larger proportion of total malignancies in China compared with the global average in 2020. Liver, gastric, oesophageal and colorectal cancers are among the most common malignancies in China, assoicated with poor prognoses and contributing greatly to the high cancer burden in the country. Life expectancy serves as a crucial metric that mirrors the social development level and health status of a population. Enhancing life expectancy stands as a key objective of the ‘Healthy China 2030’ initiative. Assessing the disease ...